Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma.
作者信息
Roy Akash
机构信息
Institute of Gastrosciences and Liver Transplantation, Apollo Multispeciality Hospitals, Kolkata: 700054, WB, India.
出版信息
J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1575-1576. doi: 10.1016/j.jceh.2022.07.003. Epub 2022 Oct 27.
Abstract
摘要
相似文献
1
Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma.IMbrave150研究的最新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌
J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1575-1576. doi: 10.1016/j.jceh.2022.07.003. Epub 2022 Oct 27.
2
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
3
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗中国不可切除肝细胞癌亚组患者：3期随机、开放标签IMbrave150研究
Liver Cancer. 2021 Jul;10(4):296-308. doi: 10.1159/000513486. Epub 2021 Apr 23.
4
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.阿替利珠单抗联合贝伐单抗对比索拉非尼治疗不可切除肝细胞癌：IMbrave150随机临床试验中老年人的结果
Liver Cancer. 2022 Jul 13;11(6):558-571. doi: 10.1159/000525671. eCollection 2022 Dec.
5
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.IMbrave150：阿替利珠单抗联合贝伐单抗与索拉非尼治疗巴塞罗那临床肝癌分期B期不可切除肝细胞癌患者的疗效和安全性：一项III期研究的探索性分析
Liver Cancer. 2022 Nov 28;12(3):238-250. doi: 10.1159/000528272. eCollection 2023 Aug.
6
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
7
Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的白蛋白-胆红素分级分析：III期IMbrave150研究的事后分析
Liver Cancer. 2023 Mar 4;12(5):479-493. doi: 10.1159/000529996. eCollection 2023 Oct.
8
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.经动脉放射性栓塞与阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌：生活质量恶化时间的匹配调整间接比较。
Adv Ther. 2022 May;39(5):2035-2051. doi: 10.1007/s12325-022-02099-0. Epub 2022 Mar 12.
9
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
10
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌的真实世界数据：符合 IMbrave150 试验纳入标准对预后的影响如何？
Target Oncol. 2023 Mar;18(2):221-233. doi: 10.1007/s11523-023-00953-x. Epub 2023 Mar 15.
引用本文的文献
1
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE, CAR-T cells, and immunotoxins in hepatocellular carcinoma.OHSV2-DSTE、CAR-T细胞和免疫毒素高阶联合在肝细胞癌中的协同抗肿瘤作用的概念性探索
Front Immunol. 2025 May 8;16:1509087. doi: 10.3389/fimmu.2025.1509087. eCollection 2025.
2
Targeting Metabolism: Innovative Therapies for MASLD Unveiled.靶向代谢：非酒精性脂肪性肝炎的创新疗法揭秘。
Int J Mol Sci. 2025 Apr 25;26(9):4077. doi: 10.3390/ijms26094077.
3
Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure.病例报告：1例错配修复缺陷（dMMR）转移性结直肠癌患者在免疫检查点抑制剂（ICI）治疗失败后接受免疫治疗联合抗血管生成治疗的长期反应
Front Oncol. 2025 Apr 9;15:1553380. doi: 10.3389/fonc.2025.1553380. eCollection 2025.
4
Hepatocellular carcinoma: signaling pathways and therapeutic advances.肝细胞癌：信号通路与治疗进展
Signal Transduct Target Ther. 2025 Feb 7;10(1):35. doi: 10.1038/s41392-024-02075-w.
5
Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma.从其他肿瘤中学习：胆管癌的进展途径与挑战应对
Cancers (Basel). 2025 Jan 6;17(1):156. doi: 10.3390/cancers17010156.
6
Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation.病例报告：肝移植中免疫检查点抑制后临床反应和排斥风险的可预测性
Front Transplant. 2023 Aug 14;2:1211916. doi: 10.3389/frtra.2023.1211916. eCollection 2023.
7
HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.HAIC 联合仑伐替尼加 PD-1 对比仑伐替尼加 PD-1 在高危晚期 HCC 患者中的疗效：一项真实世界研究。
BMC Cancer. 2024 Apr 16;24(1):480. doi: 10.1186/s12885-024-12233-6.
8
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma.他汀类药物治疗：肝细胞癌免疫治疗的潜在辅助疗法。
Front Pharmacol. 2024 Feb 1;15:1324140. doi: 10.3389/fphar.2024.1324140. eCollection 2024.
9
Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).肝癌免疫治疗的进展。
Curr Oncol. 2023 Nov 7;30(11):9789-9812. doi: 10.3390/curroncol30110711.
10
Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study.肝动脉灌注化疗联合乐伐替尼加人源化程序性死亡受体-1治疗高危晚期肝细胞癌患者：一项真实世界研究
J Hepatocell Carcinoma. 2023 Sep 6;10:1497-1509. doi: 10.2147/JHC.S418387. eCollection 2023.
本文引用的文献
1
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.阿替利珠单抗和贝伐单抗用于肝功能受损且既往接受过全身治疗的晚期肝细胞癌患者：一项真实世界经验
Ther Adv Med Oncol. 2022 Feb 26;14:17588359221080298. doi: 10.1177/17588359221080298. eCollection 2022.
2
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
3
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.一线阿替利珠单抗联合贝伐单抗与索拉非尼治疗肝细胞癌的成本效益分析
Cancers (Basel). 2021 Feb 24;13(5):931. doi: 10.3390/cancers13050931.
4
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
5
Disease Burden of Hepatocellular Carcinoma: A Global Perspective.肝癌疾病负担：全球视角。
Dig Dis Sci. 2019 Apr;64(4):910-917. doi: 10.1007/s10620-019-05537-2.
Zotero 插件